#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16888	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2053	810.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1361	1361	C	1033	C,T	969,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16888	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2053	810.8	0	HET	.	.	.	T1157C,G	.	1157	1157	T	1334	1334	T	961	T,C,G	454,407,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31320	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3612	863.1	0	.	n	.	0	T695C	SNP	695	695	T	1047	1047	C	898	C	860	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31320	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3612	863.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1689	1689	A	1068	A,G	1008,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31320	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3612	863.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2323	2323	C	1010	C,T	949,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31320	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3612	863.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2949	2949	T	980	T	944	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31320	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3612	863.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2397	2397	A	991	A	947	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2414	folP	852	852	100.0	folP.l6.c30.ctg.1	1381	172.9	1	SNP	p	R228S	1	.	.	682	684	AGC	955	957	AGC	255;257;258	A;G;C	245;243;245	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3329	177.3	1	SNP	p	S91F	0	.	.	271	273	TCC	494	496	TCC	227;226;229	T,C;C;C	213,1;215;216	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3329	177.3	1	SNP	p	D95G	0	.	.	283	285	GAC	506	508	GAC	231;233;233	G;A,G;C	213;215,1;216	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3329	177.3	1	SNP	p	D95N	0	.	.	283	285	GAC	506	508	GAC	231;233;233	G;A,G;C	213;215,1;216	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	2034	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1257	160.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	426	428	ACC	243;245;241	A,C;C;C	230,1;236;231	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	2034	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1257	160.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	441	443	CAC	232;232;228	C;A;C,T	217;216;214,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	2034	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1257	160.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	624	626	CAC	276;272;271	C;A;C	262;258;260	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	2034	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1257	160.6	1	SNP	p	G45D	0	.	.	133	135	GGC	444	446	GGC	227;227;227	G;G;C	214;212;213	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1098	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1196	91.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5468	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	178.7	1	SNP	p	D86N	0	.	.	256	258	GAC	591	593	GAC	247;249;250	G;A;C,T	229;225;229,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5468	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	178.7	1	SNP	p	S87R	0	.	.	259	261	AGT	594	596	AGT	251;249;252	A;G;T	233;232;233	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5468	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	178.7	1	SNP	p	S87W	0	.	.	259	261	AGT	594	596	AGT	251;249;252	A;G;T	233;232;233	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5468	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	178.7	1	SNP	p	S87I	0	.	.	259	261	AGT	594	596	AGT	251;249;252	A;G;T	233;232;233	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5468	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	178.7	1	SNP	p	S88P	0	.	.	262	264	TCC	597	599	TCC	254;252;253	T;C;C,A	233;235;237,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5342	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2693	197.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1550	1552	GGC	256;253;253	G;G;C	243;241;237	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1245	1247	GCA	260;264;263	G;C;A	253;253;256	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1248	1250	ATC	260;260;262	A;T;C	254;251;251	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1260	1262	GTG	269;271;270	G;T,G;G	259;262,1;259	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1260	1262	GTG	269;271;270	G;T,G;G	259;262,1;259	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1764	1766	ACC	217;221;218	A;C;C	196;204;203	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1818	1820	GCG	223;219;218	G;C;G	199;183;189	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1818	1820	GCG	223;219;218	G;C;G	199;183;189	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1941	1943	GGC	163;161;160	G;G;C	154;155;152	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1950	1952	GGC	165;166;165	G;G;C	155;156;155	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4658	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2387	193.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1968	1970	CCG	146;148;151	C,G;C,G;G	109,3;112,1;118	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5738	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2892	196.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1516	1518	CTG	208;209;211	C;T;G	189;194;190	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2798	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1840	150.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	617	617	C	198	C,T	180,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1025	1027	AAT	19;17;17	A;A;T	19;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1028	1030	AAT	17;17;17	A;A;T	17;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1040	1042	GTT	18;18;18	G;T;T	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1052	1054	GCA	19;18;19	G;C;A	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1075	1077	GTA	17;17;17	G;T;A	17;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1483	21.1	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1087	1087	G	23	G	23	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	544	546	GGA	267;269;271	G;G;A	247;252;252	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	G50D	NONSYN	148	150	GGC	550	552	GAC	268;267;267	G;A;C	245;247;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	G129S	NONSYN	385	387	GGC	787	789	AGC	174;176;178	A;G;C	169;172;172	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	805	807	CTT	178;179;181	C;T;T	165;167;170	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	829	831	GGA	196;194;196	G;G;A	183;181;180	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	D171G	NONSYN	511	513	GAT	913	915	GGT	224;224;224	G;G;T	210;211;209	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	967	969	AGC	217;215;211	A;G;C	203;201;198	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	0	.	p	.	0	T206fs	FSHIFT	616	616	A	1018	1018	A	215	A	195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	1	SNP	p	G120K	0	.	.	358	360	GGT	760	762	GGT	208;203;205	G;G;T	196;192;190	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	1	SNP	p	A121N	0	.	.	361	363	GCC	763	765	GCC	201;201;197	G;C;C	190;189;188	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2834	porB1b	1035	1035	96.35	porB1b.l15.c17.ctg.1	1581	177.5	1	SNP	p	A121D	0	.	.	361	363	GCC	763	765	GCC	201;201;197	G;C;C	190;189;188	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11326	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4977	226.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2086	2088	CAT	247;250;249	C;A;T	234;238;235	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1218	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1001	120.4	1	SNP	p	V57M	1	.	.	169	171	ATG	491	493	ATG	249;252;258	A;T;G	241;243;249	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
